Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis

Simple item page
dc.contributor.advisorSturrock, Edward
dc.contributor.advisorNtsekhe Mpiko
dc.contributor.authorFikamva, Siyavuya
dc.date.accessioned2024-04-30T13:06:38Z
dc.date.available2024-04-30T13:06:38Z
dc.date.issued2023
dc.date.updated2024-04-19T13:01:40Z
dc.description.abstractExtrapulmonary tuberculosis (EPTB) accounts for about 15% of all cases of tuberculosis (TB) globally. Tuberculous pericarditis (TBP) is a severe form of EPTB involving the pericardium that is present in 1-2% of TB cases, and poses diagnostic and therapeutic challenges, with mortality rates ranging between 8-34% despite anti- tuberculous therapy. TBP is the leading cause of pericardial constriction in Africa which is a life-threatening TBP complication. There has been significant progress towards understanding the pathogenesis of TBP. However, the mechanisms leading to the fibrotic phenotype are poorly understood, and the definitive pathophysiology is not clear. Various immune-modulatory and fibrotic cytokines, peptides, and pathways have been studied to improve our understanding of the mechanism of TBP progression. These findings prompted the investigation of the pathogenesis of TBP by identifying proteins and novel pathways that may contribute to TBP disease progression. This thesis aimed to investigate a) the molecular mechanisms involved in the development of fibrosis in TBP, and b) the potential of ACE inhibitors (ACEi) for managing fibrosis progression. Pericardial fluid was obtained from patients with TBP and patients undergoing coronary artery bypass surgery (non-infectious controls). Label-free quantitative discovery mass spectrometry (MS) was employed to investigate the TBP proteome. Proteins involved in fibrotic pathways were identified, with proteins of interest involved in wound healing, extracellular matrix (ECM) organisation, and regulation of TGF-β production. Autoantibody profiling was used to investigate whether the post-translational modification citrullination is involved in autoantibody production. Thirteen autoantibodies were expressed in the TBP pericardial fluid samples. The levels of leucine-rich repeat flightless-interacting protein 2 (LRRFIP2) were increased in TBP samples compared to in control samples. LRRFIP2 functions as part of a checkpoint connecting innate and adaptive immunity in autoimmune diseases. Finally, a systematic review was conducted to investigate the antifibrotic potential of ACEi in myocardial fibrosis. ACEi results in a significant reduction in the progression of fibrosis as monotherapy, and shows an even greater reduction in fibrosis when used in combination with other renin aldosterone angiotensin (RAAS)
dc.identifier.apacitationFikamva, S. (2023). <i>Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis</i>. (). ,Faculty of Health Sciences ,Division of Cell Biology. Retrieved from http://hdl.handle.net/11427/39534en_ZA
dc.identifier.chicagocitationFikamva, Siyavuya. <i>"Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis."</i> ., ,Faculty of Health Sciences ,Division of Cell Biology, 2023. http://hdl.handle.net/11427/39534en_ZA
dc.identifier.citationFikamva, S. 2023. Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis. . ,Faculty of Health Sciences ,Division of Cell Biology. http://hdl.handle.net/11427/39534en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Fikamva, Siyavuya AB - Extrapulmonary tuberculosis (EPTB) accounts for about 15% of all cases of tuberculosis (TB) globally. Tuberculous pericarditis (TBP) is a severe form of EPTB involving the pericardium that is present in 1-2% of TB cases, and poses diagnostic and therapeutic challenges, with mortality rates ranging between 8-34% despite anti- tuberculous therapy. TBP is the leading cause of pericardial constriction in Africa which is a life-threatening TBP complication. There has been significant progress towards understanding the pathogenesis of TBP. However, the mechanisms leading to the fibrotic phenotype are poorly understood, and the definitive pathophysiology is not clear. Various immune-modulatory and fibrotic cytokines, peptides, and pathways have been studied to improve our understanding of the mechanism of TBP progression. These findings prompted the investigation of the pathogenesis of TBP by identifying proteins and novel pathways that may contribute to TBP disease progression. This thesis aimed to investigate a) the molecular mechanisms involved in the development of fibrosis in TBP, and b) the potential of ACE inhibitors (ACEi) for managing fibrosis progression. Pericardial fluid was obtained from patients with TBP and patients undergoing coronary artery bypass surgery (non-infectious controls). Label-free quantitative discovery mass spectrometry (MS) was employed to investigate the TBP proteome. Proteins involved in fibrotic pathways were identified, with proteins of interest involved in wound healing, extracellular matrix (ECM) organisation, and regulation of TGF-β production. Autoantibody profiling was used to investigate whether the post-translational modification citrullination is involved in autoantibody production. Thirteen autoantibodies were expressed in the TBP pericardial fluid samples. The levels of leucine-rich repeat flightless-interacting protein 2 (LRRFIP2) were increased in TBP samples compared to in control samples. LRRFIP2 functions as part of a checkpoint connecting innate and adaptive immunity in autoimmune diseases. Finally, a systematic review was conducted to investigate the antifibrotic potential of ACEi in myocardial fibrosis. ACEi results in a significant reduction in the progression of fibrosis as monotherapy, and shows an even greater reduction in fibrosis when used in combination with other renin aldosterone angiotensin (RAAS) DA - 2023 DB - OpenUCT DP - University of Cape Town KW - Medicine LK - https://open.uct.ac.za PY - 2023 T1 - Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis TI - Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis UR - http://hdl.handle.net/11427/39534 ER - en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/39534
dc.identifier.vancouvercitationFikamva S. Investigating the pathways involved in the progression of fibrosis in tuberculous pericarditis. []. ,Faculty of Health Sciences ,Division of Cell Biology, 2023 [cited yyyy month dd]. Available from: http://hdl.handle.net/11427/39534en_ZA
dc.language.rfc3066Eng
dc.publisher.departmentDivision of Cell Biology
dc.publisher.facultyFaculty of Health Sciences
dc.subjectMedicine
dc.titleInvestigating the pathways involved in the progression of fibrosis in tuberculous pericarditis
dc.typeThesis / Dissertation
dc.type.qualificationlevelMasters
dc.type.qualificationlevelMSc
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
thesis_hsf_2023_fikamva siyavuya.pdf
Size:
2.32 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.72 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Masters